Toshimitsu Yamaoka

and Amplifications Mediate Resistance to Rociletinib and Osimertinib in Acquired Afatinib-Resistant NSCLC Harboring Exon 19 Deletion/T790M in .

Phase I study of the combination of gemcitabine and nedaplatin for treatment of previously untreated advanced non-small cell lung cancer.

Regulation of apoptosis during homeostasis and disease in the intestinal epithelium.

[Two cases of successfully treated invasive pulmonary aspergillosis following influenza virus infection].

Effectiveness of intensive follow-up after response in patients with small cell lung cancer.

[Two cases with recurrent non-small cell lung cancer successfully treated with cisplatin and S-1].

Patient satisfaction with sedation for flexible bronchoscopy.

Transactivation of EGF receptor and ErbB2 protects intestinal epithelial cells from TNF-induced apoptosis.

Patient willingness to undergo chemotherapy and thoracic radiotherapy for locally advanced non-small cell lung cancer.

Preventive and therapeutic effects of imatinib in Wistar-Kyoto rats with anti-glomerular basement membrane glomerulonephritis.

Phase II study of the combination of nedaplatin and weekly paclitaxel in patients with advanced non-small cell lung cancer.

Combination effect between bortezomib and tumor necrosis factor alpha on gefitinib-resistant non-small cell lung cancer cell lines.

Induction chemoradiotherapy followed by surgery for locally advanced non-small cell lung cancer.

[Chemotherapy-induced myelosuppression and treatment efficacy in extensive-stage small cell lung cancer].

IL-17A and IL-17F stimulate chemokines via MAPK pathways (ERK1/2 and p38 but not JNK) in mouse cultured mesangial cells: synergy with TNF-alpha and IL-1beta.

The UGT1A1*28 genotype and the toxicity of low-dose irinotecan in patients with advanced lung cancer.

Are levels of pro-gastrin-releasing peptide or neuron-specific enolase at relapse prognostic factors after relapse in patients with small-cell lung cancer?

Phase II study of S-1, a novel oral fluoropyrimidine, and biweekly administration of docetaxel for previously treated advanced non-small-cell lung cancer.

Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer.

Phase II trial of the combination of carboplatin and irinotecan in elderly patients with small-cell lung cancer.

Specific epidermal growth factor receptor autophosphorylation sites promote mouse colon epithelial cell chemotaxis and restitution.

[A case of pulmonary aspergilloma concomitant with allergic bronchopulmonary aspergillosis].

[The mechanisms of resistance to EGFR-TKIs and challenges to overcome resistance in EGFR mutant non-small cell lung cancer].

Myelosuppression induced by concurrent chemoradiotherapy as a prognostic factor for patients with locally advanced non-small cell lung cancer.

Relationship of circulating tumor cells to the effectiveness of cytotoxic chemotherapy in patients with metastatic non-small-cell lung cancer.

Evaluation of the safety and efficacy of combination chemotherapy with vinorelbine and platinum agents for patients with non-small cell lung cancer with interstitial lung disease.

Phase II study of concurrent chemoradiotherapy with carboplatin and vinorelbine for locally advanced non-small-cell lung cancer.

Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.

Acquired Resistance Mechanisms to Combination Met-TKI/EGFR-TKI Exposure in Met-Amplified EGFR-TKI-Resistant Lung Adenocarcinoma Harboring an Activating EGFR Mutation.

Distinct Afatinib Resistance Mechanisms Identified in Lung Adenocarcinoma Harboring an EGFR Mutation.

Up-regulation of Syndecan-4 contributes to TGF-β1-induced epithelial to mesenchymal transition in lung adenocarcinoma A549 cells.

Molecular-Targeted Therapies for Epidermal Growth Factor Receptor and Its Resistance Mechanisms.

Receptor Tyrosine Kinase-Targeted Cancer Therapy.